followed by exhaustive absorptions with normal human tissues. On the other hand, human tumours often produce oncofoetal proteins such as carcinoembryonic antigen and alphafoetoprotein which are expressed in a wide variety of tumours, and are also used as markers in the follow-up of patients (Gold & Freedman, 1965; Sell & Becker, 1978) . Antibodies against these oncofoetal antigens might be good candidates as carriers of chemotherapeutic 57* Accepted 10 January 1980 agents to the cancer cells producing oncofoetal markers.
Our study is an in vitro evaluation of the efficiency of this new approach of immunochemotherapy. We have used the anthracycline Daunomycin (RhonePoulenc) covalently bound to anti-alphafoetoprotein (anti-AFP) immunoglobulins as specific carriers to the BW-7756 mouse hepatoma cells producing AFP. Binding was performed in the presence of glutaraldehyde, and the protein fraction was subsequently separated from the free drug by chromatography on Sephadex G-25 (Pharmacia Fine Chemicals) (Hurwitz et al., 1975) . The binding ratio used in the experiments was about 4 mol of drug per mol of protein, and the concentration of drug was 0 5 ig/ml of culture medium. Fig. 1 shows that when 3 x 103 hepatoma cells are incubated with the conjugate for short periods of time, washed and reincubated in fresh culture medium for a long-term culture, they lose their ability to proliferate and form colonies. This drastic effect is observed with the conjugate within 6 h as compared to a 1-day incubation to obtain the same effect with the drug alone or with the physical mixture of the drug and the antibody. This points to the specificity of the conjugate and its rapid adherence on to the cells. seen with the physical mixture of the drug and the antibody. For any concentration of drug used, the greatest cell killing was found with the use of the Daunomycinanti-AFP conjugate. The Table shows that, when compared to a nonspecific macromolecule (bovine serum albumin) used as a carrier for the drug, the specific antibody-Daunomycin conjugate was a significantly more effective inhibitor of colony formation and [3H]TdR incorporation, thus showing the specificity of the system.
Our results indicate that Daunomycin covalently bound to specific anti-oncofoetal protein antibodies presents a superior antitumour activity relative to the free drug, the free antibody, the mixture of both agents or to a nonspecific macromolecule as the carrier for the chemotherapeutic agent. Such an increased cell killing with the specific conjugate in these in vitro experiments was unexpected. Our results also suggest that the synergistic effect of the physical mixture of the 2 substances is not the unique process involved. The complete mechanism is still unknown.
However, this new approach offers a potential clinical application, since the specificity of the conjugates for the tumour cells may reduce the systemic toxicity of the chemotherapeutic agents. This is being tested in vivo on tumour-bearing animals.
